Blurbs

Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV), Agilon Health (AGL) and Axsome Therapeutics (AXSM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Minerva Neurosciences (NERVResearch Report), Agilon Health (AGLResearch Report) and Axsome Therapeutics (AXSMResearch Report).

Minerva Neurosciences (NERV)

BTIG analyst Thomas Shrader maintained a Buy rating on Minerva Neurosciences yesterday and set a price target of $6.00. The company’s shares closed last Monday at $4.59, close to its 52-week low of $2.51.

According to TipRanks.com, Shrader is a 1-star analyst with an average return of -0.8% and a 31.6% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Acumen Pharmaceuticals, Aldeyra Therapeutics, and Pliant Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Minerva Neurosciences with a $13.50 average price target, which is a 310.3% upside from current levels. In a report issued on August 10, JMP Securities also reiterated a Buy rating on the stock with a $21.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Agilon Health (AGL)

In a report released yesterday, David Larsen from BTIG maintained a Hold rating on Agilon Health. The company’s shares closed last Monday at $21.20.

According to TipRanks.com, Larsen has 0 stars on 0-5 stars ranking scale with an average return of -8.4% and a 34.0% success rate. Larsen covers the Technology sector, focusing on stocks such as Health Catalyst, American Well, and Sharecare.

Currently, the analyst consensus on Agilon Health is a Strong Buy with an average price target of $31.20.

Axsome Therapeutics (AXSM)

In a report issued on August 19, Robert Hazlett from BTIG reiterated a Buy rating on Axsome Therapeutics, with a price target of $62.00. The company’s shares closed last Monday at $64.46.

According to TipRanks.com, Hazlett is a 3-star analyst with an average return of 3.3% and a 38.6% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Homology Medicines, and Matinas BioPharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Axsome Therapeutics with a $71.89 average price target, implying a 20.8% upside from current levels. In a report issued on August 10, Cantor Fitzgerald also maintained a Buy rating on the stock with a $54.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NERV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos